Accelerated Approval

Accelerated Approval
Name	Accelerated Approval
Agency	Food and Drug Administration
Introduced	1992
Purpose	Expedite access to therapies
Scope	United States
Related	Fast Track (drug)], :Category:Regulatory science?

Accelerated Approval Accelerated Approval is a regulatory pathway for expediting access to medical products that address serious or life‑threatening conditions, using surrogate or intermediate clinical endpoints. It balances earlier availability of therapies with requirements for later verification of clinical benefit, involving stakeholders such as the Food and Drug Administration, pharmaceutical firms like Pfizer, biotechnology companies such as Genentech, patient advocacy groups including American Cancer Society, and payers like Centers for Medicare and Medicaid Services. The pathway sits alongside other mechanisms like Breakthrough Therapy designation, Priority Review, and programs influenced by statutes such as the Food, Drug, and Cosmetic Act.

Overview

The Accelerated Approval pathway authorizes marketing based on surrogate endpoints that are reasonably likely to predict clinical benefit, allowing earlier patient access for conditions such as oncology indications pursued by Merck and rare diseases treated by developers like Vertex Pharmaceuticals. Sponsors submit evidence from clinical studies often involving biomarkers used in settings from oncology trials at institutions like Memorial Sloan Kettering Cancer Center to virology research at Centers for Disease Control and Prevention. The design reflects regulatory strategies seen in programs at agencies such as the European Medicines Agency and Pharmaceuticals and Medical Devices Agency in Japan.

History and Legislative Background

Legislative roots trace to amendments and policy debates in the early 1990s involving Congress members such as Orrin Hatch and driven by crises like the HIV/AIDS epidemic with advocacy from organizations including ACT UP. The 1992 statute amended the Food, Drug, and Cosmetic Act to permit approvals based on surrogate endpoints after deliberations in bodies like the United States Congress and committees chaired by figures including John Dingell. Influential cases and policy documents from agencies including the National Institutes of Health and legal analyses from institutions like Harvard Law School shaped subsequent guidances issued by the Food and Drug Administration. Court decisions involving companies such as Amgen and disputes over labeling and enforcement further refined practice.

Eligibility Criteria and Approval Process

Eligibility focuses on products for serious or life‑threatening conditions such as cancers treated in trials at Dana-Farber Cancer Institute or genetic disorders managed by centers like Mayo Clinic. Sponsors propose surrogate or intermediate clinical endpoints—examples include tumor response rates observed in collaborations with academic centers like Johns Hopkins University and virological markers measured at World Health Organization‑aligned labs. FDA review involves divisions such as the Center for Drug Evaluation and Research and advisory committees that include experts from American Society of Clinical Oncology and representatives from patient groups like Patient-Centered Outcomes Research Institute. The process includes protocol negotiations, rolling submissions, and labeling stipulations akin to mechanisms used in Priority Review and Breakthrough Therapy designation.

Post-Approval Requirements and Confirmatory Trials

Approvals are conditional on post‑marketing confirmatory trials intended to verify clinical benefit; sponsors such as Novartis and AstraZeneca must conduct studies often registered at platforms like ClinicalTrials.gov and coordinated with institutions including National Cancer Institute. Confirmatory studies may be randomized controlled trials run at research networks like Alliance for Clinical Trials in Oncology or pragmatic studies informed by payers such as Centers for Medicare and Medicaid Services. Failure to verify benefit can prompt regulatory actions including label changes, market withdrawal proceedings led by the Food and Drug Administration, and litigation in federal courts such as the United States Court of Appeals for the District of Columbia Circuit.

Controversies and Criticisms

Critiques involve concerns from clinicians and scholars at institutions like Johns Hopkins Bloomberg School of Public Health and think tanks such as the Brookings Institution about reliance on surrogate endpoints used by developers like Illumina or trial designs promoted by proponents including Eli Lilly. Debates include high prices set by companies such as Gilead Sciences for therapies approved via this pathway, transparency of confirmatory trial timelines raised by advocacy groups like Patients for Affordable Drugs, and methodological disputes highlighted in journals edited by scholars from Yale School of Medicine. Warning letters and enforcement actions by the Food and Drug Administration and discussions in legislative bodies such as the United States Senate underscore tensions among regulators, industry, payers, and patient advocates.

International Implementations and Comparisons

Parallel expedited pathways exist at the European Medicines Agency under conditional marketing authorizations and in Japan via the Pharmaceuticals and Medical Devices Agency, with comparative analyses by organizations such as the Organisation for Economic Co-operation and Development and academic centers like University of Oxford. National health technology assessment agencies, including the National Institute for Health and Care Excellence and Institute for Clinical and Economic Review, evaluate real‑world evidence from registries run by entities like ICD‑10 coordination centers to inform reimbursement decisions. Cross‑jurisdictional harmonization efforts involve multilateral dialogues among regulators including the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

Category:Drug regulation